Comparing two methods for stopping high flow nasal cannula treatment in infants with acute bronchiolitis
High Flow Nasal Cannula Weaning in Acute Bronchiolitis - an Open-label Randomized Controlled Trials
This study is testing whether stopping high flow nasal cannula treatment right away or gradually is better for helping infants with acute bronchiolitis leave the hospital sooner and safely.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 0 Months to 12 Months |
| Sex | All |
| Sponsor | Kuopio University Hospital Academic / other |
| Locations | 4 sites (Joensuu and 3 other locations) |
| Trial ID | NCT06321133 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to compare two strategies for discontinuing high flow nasal cannula treatment in infants diagnosed with acute bronchiolitis. One group will have their treatment stopped immediately, while the other will undergo a gradual weaning process. The study will assess whether immediate cessation can shorten hospitalization time and determine the safety of this approach. Given the lack of effective pharmacological treatments for acute bronchiolitis, this research seeks to provide evidence-based guidance on the management of this common condition in infants.
Who should consider this trial
Good fit: Ideal candidates for this study are infants diagnosed with acute bronchiolitis who have been on high flow nasal cannula treatment for at least 12 hours and have stable oxygen saturation.
Not a fit: Patients with major congenital anomalies of the lungs, heart, or diaphragm, or those with bacterial pneumonia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to shorter hospital stays for infants suffering from acute bronchiolitis.
How similar studies have performed: While other observational studies have suggested that immediate cessation may be beneficial, this is the first randomized trial specifically focused on bronchiolitis patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically diagnosed acute bronchiolitis * High flow nasal cannula treatment has lasted for at least 12 hours * Measured saturation 95 or more with room air * High flow rate is maximum 2l/kg/min * The treating doctors considers the infant suitable to be without high flow Exclusion Criteria: * Major congenital anomaly of lungs, hearts or diaphragm * Bacterial pneumonia * Parents do not give consent
Where this trial is running
Joensuu and 3 other locations
- Siun Sote — Joensuu, Finland (Recruiting)
- Central Finland Hospital District — Jyväskylä, Finland (Recruiting)
- Kuopio University Hospital — Kuopio, Finland (Recruiting)
- Mikkeli Central Hospital — Mikkeli, Finland (Recruiting)
Study contacts
- Study coordinator: Ilari Kuitunen, MD, PhD
- Email: ilari.kuitunen@uef.fi
- Phone: +358447174910
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.